OBJECTIVES: A nested case-control study was conducted in Miami, Fla, to determine risk factors associated with human immunodeficiency virus type 1 (HIV-1) seroconversion among injection drug users. METHODS: The study identified 21 incident cases of HIV-1 infection and 76 unmatched controls from two longitudinal cohorts of injection drug users. One cohort consisted of individuals who originally had been recruited from treatment centers; a second cohort was recruited from the "street." Logistic regression analyses that adjusted for age, gender, and race were performed. RESULTS: The final model determined that the primary independent risk factor that best explained the risk for seroconversion was sharing injection equipment in the year prior to conversion; a marginal risk factor was presence of sexually transmitted disease during this same period. CONCLUSIONS: Both an injection component and a sexual component play a role in seroconversion among injection drug users, although the injection component is much stronger.
OBJECTIVES: A nested case-control study was conducted in Miami, Fla, to determine risk factors associated with human immunodeficiency virus type 1 (HIV-1) seroconversion among injection drug users. METHODS: The study identified 21 incident cases of HIV-1 infection and 76 unmatched controls from two longitudinal cohorts of injection drug users. One cohort consisted of individuals who originally had been recruited from treatment centers; a second cohort was recruited from the "street." Logistic regression analyses that adjusted for age, gender, and race were performed. RESULTS: The final model determined that the primary independent risk factor that best explained the risk for seroconversion was sharing injection equipment in the year prior to conversion; a marginal risk factor was presence of sexually transmitted disease during this same period. CONCLUSIONS: Both an injection component and a sexual component play a role in seroconversion among injection drug users, although the injection component is much stronger.
Authors: N Romano; F Vitale; D R Alesi; F Bonura; R La Licata; V Intonazzo; G Dardanoni; C Mammina Journal: Am J Epidemiol Date: 1992-06-01 Impact factor: 4.897
Authors: Christina S Meade; Roger D Weiss; Garrett M Fitzmaurice; Sabrina A Poole; Geetha A Subramaniam; Ashwin A Patkar; Hilary S Connery; George E Woody Journal: J Acquir Immune Defic Syndr Date: 2010-09 Impact factor: 3.731
Authors: Erin Gregory Romero; Linda A Teplin; Gary M McClelland; Karen M Abram; Leah J Welty; Jason J Washburn Journal: Pediatrics Date: 2007-05 Impact factor: 7.124
Authors: Yan Yao; Ning Wang; Jennifer Chu; Guowei Ding; Xia Jin; Yongli Sun; Guixiang Wang; Junjie Xu; Kumi Smith Journal: Int J Infect Dis Date: 2008-09-07 Impact factor: 3.623